One To Watch

Genmab

Company Overview

A Copenhagen-based antibody specialist focused on oncology, Genmab develops differentiated bispecific and next-generation antibody therapies for hematologic and solid tumor cancers through proprietary technology platforms and major pharma partnerships. The company's commercial portfolio includes Epkinly (epcoritamab) for lymphoma, co-developed with AbbVie, while royalties from Johnson and Johnson's Darzalex (daratumumab) and Novartis' Kesimpta (ofatumumab) generate substantial recurring revenue. Genmab reported total revenue of $1.02 billion in the third quarter of 2025, beating analyst estimates of $966 million — a 25% year-on-year increase. The company is expanding its pipeline footprint through acquisitions, licensing deals, and AI-enabled clinical development partnerships.

Headquarters and Global Presence

Genmab is headquartered in Copenhagen, Denmark, and trades on both Nasdaq (GMAB) and Nasdaq Copenhagen. The company has operational presences across the United States and Europe, with recent appointments of dedicated general managers for the US and UK markets reflecting an active commercial expansion strategy.

Founding and History

Genmab was founded in 1999 and has grown from a pure antibody discovery platform into a fully integrated oncology biotechnology company. A pivotal strategic move came in 2024 when the company acquired ProfoundBio for approximately $1.8 billion, gaining a portfolio of antibody-drug conjugates. In September 2025, Genmab announced a further pipeline expansion through a takeover bid for Dutch clinical-stage biotech Merus, whose shares surged nearly 38% on the news. The Merus acquisition signals a continued intent to build out multispecific antibody capabilities beyond Genmab's traditional bispecific focus.

Therapy Areas and Focus

Genmab concentrates almost exclusively on oncology, with particular depth in hematologic malignancies including multiple myeloma, follicular lymphoma, and diffuse large B-cell lymphoma. Its royalty-generating assets address B-cell malignancies and multiple sclerosis, while its pipeline increasingly targets solid tumors through ADC and multispecific platforms. The company discontinued acasunlimab, its anti-PVRIG antibody being investigated in lung cancer, in January 2026, citing a reassessment of pipeline priorities. Hematology remains the commercial and clinical core, with solid tumor programs now advancing through the Merus acquisition and ADC development.

Technology Platforms and Modalities

Genmab's foundational technology platforms include DuoBody, its proprietary bispecific antibody engineering system, and HexaBody, which creates hexamerization-enhanced antibodies designed to amplify complement-dependent cytotoxicity. The DuoBody platform underpins epcoritamab, a CD3xCD20 bispecific T-cell engager that redirects cytotoxic T cells to eliminate malignant B cells. Through the ProfoundBio acquisition, Genmab gained access to a differentiated ADC platform, although GEN1107, one of the derived ADC assets, was discontinued in September 2025 after a Phase I/II trial was terminated on benefit-risk grounds. A licensing deal with Revitope Oncology, signed in late 2024, adds conditional T-cell engager technology (TwoGATE) to the platform toolkit, potentially enabling tumor-selective T-cell redirection.

Key Pipeline and Programs

Epcoritamab (Epkinly) is Genmab's most advanced commercial and clinical asset — a subcutaneously administered CD3xCD20 bispecific T-cell engager co-developed with AbbVie. It received FDA approval in June 2024 and has generated strong uptake in relapsed/refractory diffuse large B-cell lymphoma. A Phase III study in follicular lymphoma reported a decisive positive readout in August 2025, potentially supporting the first approved bispecific combination regimen in the second-line setting; however, subsequent top-line results in January 2026 were characterized as disappointing, sending shares down approximately 5%. HexaBody-CD38 (GEN301) is a hexamerization-enhanced anti-CD38 antibody investigated in multiple myeloma and other CD38-expressing hematologic cancers that showed promising Phase I/II trial results; Johnson and Johnson opted not to exercise its option to license the asset in March 2025, returning the program to Genmab for independent development. Pipeline assets derived from the Merus acquisition, which brings biclonics and multispecific antibody programs with activity in solid tumors, are expected to broaden Genmab's clinical-stage portfolio in the near term.

Recent Developments

In January 2026, Genmab announced the discontinuation of acasunlimab across all lung cancer indications, ending a collaboration that had previously seen rights returned from BioNTech in August 2024. That same month, the company reported disappointing top-line results for an epcoritamab study, triggering a 5% share price decline, and announced a partnership with AI company Anthropic to deploy Claude-powered agentic tools across clinical development operations, including data processing and regulatory document generation. The Merus acquisition, announced in September 2025, remains the most consequential strategic move of the period, adding multispecific antibody capabilities to Genmab's platform. Full-year 2025 revenue guidance was raised following strong first- and second-quarter results.

Key Personnel

Jan van de Winkel serves as President and Chief Executive Officer; he co-founded Genmab and has led the company since its inception, building it from a platform technology play into a billion-dollar revenue oncology business. Leslie Amendola was appointed Senior Vice President and General Manager of the US business in January 2025, taking charge of the company's growing commercial presence in its largest market. Matt Kiely joined as General Manager for the UK in September 2025, supporting Genmab's expanding European commercial infrastructure.

Strategic Partnerships

Genmab's most significant partnership is with AbbVie for epcoritamab, which covers co-development and commercialization of Epkinly globally; the relationship has also generated legal friction, with AbbVie filing a misappropriation complaint in a US federal court in March 2025, which Genmab stated it intends to contest. Johnson and Johnson remains a key royalty partner through its commercialization of Darzalex (daratumumab), which continues to be a primary revenue driver alongside Novartis' Kesimpta (ofatumumab). The October 2024 license agreement with Revitope Oncology and the January 2026 Anthropic AI collaboration round out a partnership strategy that spans biology, technology, and clinical operations.

FAQ Section

Genmab generates the majority of its revenue from royalties on partnered products — principally daratumumab (Darzalex) and ofatumumab (Kesimpta) — which provide stable, high-margin cash flows that fund internal R&D. The company is deliberately shifting toward greater ownership of its pipeline, exemplified by the $1.8 billion ProfoundBio acquisition in 2024 and the Merus takeover bid in 2025. Epkinly's growing commercial uptake in lymphoma represents the clearest example of Genmab building direct commercial value rather than licensing it downstream.

CD3xCD20 bispecifics like epcoritamab physically link cytotoxic T cells to CD20-expressing malignant B cells, inducing targeted killing without requiring a pre-existing antitumor immune response. This mechanism is particularly relevant in patients who have relapsed after or are refractory to prior CD20-directed therapies, including rituximab-based regimens and CAR-T cell therapy. The subcutaneous administration of epcoritamab also offers a practical advantage over intravenous bispecifics, supporting outpatient dosing and broader accessibility.

HexaBody antibodies are engineered to self-assemble into hexameric ring structures on the surface of target cells, dramatically amplifying complement activation compared to standard IgG antibodies. This enhanced complement-dependent cytotoxicity can produce stronger tumor cell killing at lower antibody concentrations. HexaBody-CD38 (GEN301) demonstrated promising results in Phase I/II trials in myeloma, and while Johnson and Johnson passed on licensing it in March 2025, Genmab retains full development rights to pursue the asset independently.

Epkinly received FDA approval in June 2024 and has achieved meaningful commercial uptake in relapsed/refractory diffuse large B-cell lymphoma. A Phase III study in follicular lymphoma delivered a positive readout in August 2025, potentially supporting approval in the second-line combination setting. However, separate top-line data released in January 2026 were characterized as disappointing, and the program's ultimate regulatory scope in follicular lymphoma remains to be fully defined. Epcoritamab is co-commercialized globally with AbbVie.

Hematologic malignancies — particularly B-cell lymphomas and multiple myeloma — remain the commercial and clinical core of Genmab's portfolio. The ProfoundBio acquisition was intended to extend the pipeline into solid tumors via ADCs, though the discontinuation of GEN1107 in September 2025 illustrates the challenges of that expansion. The Merus acquisition brings multispecific antibody programs with solid tumor activity, and the conditional T-cell engager license from Revitope could open tumor-selective immunotherapy approaches in indications beyond hematology.

Genmab is a commercially active, revenue-generating biotechnology company, with over $1 billion in quarterly revenue reported in Q3 2025 and a growing commercial product in Epkinly. Pipeline development spans Phase I through Phase III, with the Merus acquisition expected to add earlier-stage multispecific programs. Near-term milestones include clarifying the regulatory path for epcoritamab in follicular lymphoma following the mixed January 2026 data, advancing HexaBody-CD38 independently, and integrating Merus assets into the broader pipeline strategy.

Genmab sits at an inflection point between a royalty-funded platform business and an independent commercial oncology company. Key watchpoints include:

Want to Update your Company's Profile?